SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)


  • Org Study ID: 7902-011
  • Secondary ID: 2018-003752-21,MK-7902-011,E7080-G000-317,LEAP-011,194808
  • NCT ID: NCT03898180
  • NCT Alias:
  • Sponsor: Merck Sharp & Dohme Corp. - Industry
  • Source: Merck Sharp & Dohme Corp.

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of lenvatinib (MK-7902/E7080) in combination with pembrolizumab (MK-3475) in the treatment of cisplatin-ineligible participants with a Programmed Cell Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, or in participants ineligible for any platinum-containing chemotherapy regardless of CPS, with advanced/unresectable or metastatic urothelial carcinoma (UC). The primary hypotheses for this study are that: 1. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR), and 2. Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Overall Survival (OS).

Overal Status Start Date Phase Study Type
Recruiting May 6, 2019 Phase 3 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

Primary Outcome 1 - Time Frame: Up to approximately 40 months

Primary Outcome 2 - Measure: Overall Survival (OS)

Primary Outcome 2 - Time Frame: Up to approximately 40 months

Condition:

  • Urothelial Carcinoma

Eligibility

Criteria:
Inclusion Criteria:

- Has a histologically or cytologically confirmed diagnosis of advanced/unresectable
(inoperable) or metastatic urothelial carcinoma (UC) of the renal pelvis, ureter
(upper urinary tract), bladder, or urethra.
>
- Has ≥1 measurable target lesion per RECIST 1.1 as assessed by the local site
investigator/radiologist.

- Has provided an archival tumor tissue sample or newly obtained core or excisional
biopsy of a tumor lesion not previously irradiated and adequate for Programmed
Death-Ligand 1 (PD-L1) evaluation.

- Has received no prior systemic chemotherapy for advanced or metastatic UC with the
following exceptions:

- Neoadjuvant (prior to surgery) platinum-based chemotherapy for treatment of
muscle-invasive bladder cancer with recurrence >12 months from completion of the
therapy is permitted.

- Adjuvant (following surgery) platinum-based chemotherapy following radical cystectomy,
with recurrence >12 months from completion of the therapy, is permitted.

- Meets criteria for either option a or option b (below):

- a. Has a tumor(s) with PD-L1 combined positive score (CPS) ≥10 and is considered
ineligible to receive cisplatin-based combination therapy, based on 1 of the
following:

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 2 within 7
days prior to randomization

- National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Version 4.0 Grade ≥2 audiometric hearing loss

- NCI CTCAE Version 4.0 Grade ≥2 peripheral neuropathy OR

- b. In the opinion of the investigator, is considered ineligible to receive any
platinum-based chemotherapy (i.e., ineligible for cisplatin and carboplatin) based on:

- ECOG PS of 2 within 7 days prior to randomization. and ≥1 of the following:

- Documented visceral metastatic disease

- NCI CTCAE Version 4.0 Grade ≥2 audiometric hearing loss

- NCI CTCAE Version 4.0 Grade ≥2 peripheral neuropathy

- Other reason for the participant's being unable to receive both cisplatin and
carboplatin safely. Additional criteria for platinum ineligibility will be considered
and allowed on a case-by-case basis, following consultation with the Sponsor. Note:
Participants considered ineligible for any platinum-based chemotherapy are eligible
for this study regardless of their tumor PD-L1 status.

- Has ECOG PS 0, 1, or 2 within 7 days prior to randomization and a life expectancy of
≥3 months.

- Male participants are eligible to participate if they agree to the following during
the treatment period and for ≥30 days after the last dose of pembrolizumab or
lenvatinib/placebo:

- Be abstinent from heterosexual intercourse as their preferred and usual lifestyle and
agree to remain abstinent, OR

- Must agree to use contraception unless confirmed to be azoospermic (vasectomized or
secondary to medical cause as detailed below:

- Agrees to use a male condom plus partner use of an additional contraceptive method
when having penile-vaginal intercourse with a woman of childbearing potential (WOCBP)
who is not currently pregnant. Note: Men with a pregnant or breastfeeding partner must
agree to remain abstinent from penile-vaginal intercourse or use a male condom during
each episode of penile-vaginal penetration.

- A female participant is eligible to participate if she is not pregnant or
breastfeeding and if she is not a WOCBP OR is a WOCBP and is using a contraceptive
method that is highly effective (with a failure rate of <1% per year) with low user
dependency, or is abstinent from heterosexual intercourse as her preferred and usual
lifestyle during the intervention period and for ≥120 days post pembrolizumab or ≥30
days post lenvatinib/placebo.

- Has adequately controlled blood pressure (BP) with or without antihypertensive
medications, defined as BP ≤150/90 mm Hg at screening and no change in
antihypertensive medications within 1 week prior to randomization.

- Has adequate organ function.

Exclusion Criteria:

- Has disease that is suitable for local therapy administered with curative intent (e.g.
chemotherapy and radiation for Stage 3 disease).

- Has tumor with any neuroendocrine or small cell component.

- Has a history of a gastrointestinal condition or procedure (e.g. gastric bypass,
malabsorption) that, in the opinion of the investigator, may affect oral drug
absorption.

- Has had major surgery within 3 weeks prior to the first dose of study treatment

- Has a pre-existing Grade ≥3 gastrointestinal or non-gastrointestinal fistula.

- Has radiographic evidence of major blood vessel invasion/infiltration, or has had
clinically significant hemoptysis (≥0.5 teaspoon of bright red blood) or tumor
bleeding within 2 weeks prior to the first dose of study treatment.

- Has had significant cardiovascular impairment within 12 months of the first dose of
study treatment, such as history of New York Heart Association (NYHA) >Class II
congestive heart failure, unstable angina, myocardial infarction or cerebrovascular
accident (CVA)/stroke, cardiac revascularization procedure, or cardiac arrhythmia
associated with hemodynamic instability.

- Has known intolerance or severe hypersensitivity (Grade ≥3) to pembrolizumab or
lenvatinib or any of their excipients

- Has received lenvatinib as monotherapy or in combination with a programmed cell
death-1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitor or has previously been
enrolled in a clinical study evaluating lenvatinib for bladder cancer, regardless of
the treatment received.

- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 inhibitor,
indoleamine-pyrrole 2,3 dioxygenase (IDO1) inhibitor, or agent directed to another
stimulatory or co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated
antigen 4 [CTLA-4], OX 40, CD137), or any other antibody or drug targeting T-cell
costimulatory pathways in the adjuvant or advanced/metastatic setting.

- Has received prior radiotherapy to a metastatic site without the use of chemotherapy
radiosensitization within 3 weeks of the first dose of study treatment, with the
exception of palliative radiotherapy to bone lesions, which is allowed if completed 2
weeks before the start of study treatment. Participants must have recovered from all
radiation-related toxicities, and must not require corticosteroids.

- Has received a live vaccine within 30 days prior to the first dose of study treatment.

- In the investigator's judgment, has not recovered from toxicity or other complications
from any major surgery prior to starting study treatment.

- Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 4 weeks prior to the first dose of
study treatment. Note: Participants who have entered the follow-up phase of an
investigational study may participate as long as it has been 4 weeks after the last
dose of the previous investigational agent.

- Has history or presence of an abnormal electrocardiogram (ECG) that, in the
investigator's opinion, is clinically meaningful.

- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (at a
dose exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to randomization.

- Has had an active malignancy (except locally advanced or metastatic UC) within the
past 36 months. Note: Participants with basal cell carcinoma of the skin, squamous
cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical
cancer in situ) who have undergone potentially curative therapy are not excluded.

- Has a history of prostate cancer (T2NXMX or lower with Gleason score ≤7) treated with
definitive intent (surgically or with radiation therapy) ≥1 year prior to study entry
is acceptable, provided that the participant is considered prostate cancer-free.

- Has central nervous system (CNS) metastases, unless the participant has completed
local therapy (e.g. whole brain radiation therapy, surgery, or radiosurgery) and has
discontinued use of corticosteroids for this indication for ≥4 weeks before starting
study treatment. Any signs (e.g. radiologic) or symptoms of CNS metastases must be
stable for ≥4 weeks before starting study treatment.

- Has an active autoimmune disease that has required systemic treatment in the past 2
years (i.e, with disease-modifying agents, corticosteroids, or immunosuppressive
drugs).

- Has a history of (non-infectious) pneumonitis that required systemic steroids, or
current pneumonitis.

- Has an active infection requiring systemic therapy.

- Has a known history of human immunodeficiency virus (HIV) infection.

- Has a known history of or is positive for active hepatitis B virus (HBV) or has active
hepatitis C virus (HCV).

- Has active tuberculosis (TB).

- Is receiving hemodialysis.

- Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of pembrolizumab and lenvatinib/placebo.

- Has had an allogeneic tissue/solid organ transplant.
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Medical Director

Role: Study Director

Affiliation: Merck Sharp & Dohme Corp.

Overall Contact

Name: Toll Free Number

Phone: 1-888-577-8839

Email: Trialsites@merck.com

Locations

Facility Status Contact
Banner MD Anderson Cancer Center ( Site 0016)
Gilbert, Arizona 85234
United States
Recruiting Study Coordinator
480-256-3425
John Wayne Cancer Institute ( Site 0017)
Santa Monica, California 90404
United States
Recruiting Study Coordinator
310-449-5224
University of Chicago ( Site 0039)
Chicago, Illinois 60637
United States
Recruiting Study Coordinator
773-834-1580
Joliet Oncology Hematology ( Site 0091)
Joliet, Illinois 60436
United States
Recruiting Study Coordinator
815-730-3098
Quincy Medical Group ( Site 0022)
Quincy, Illinois 62301
United States
Recruiting Study Coordinator
217-222-6550
New England Cancer Specialists ( Site 0047)
Scarborough, Maine 04074
United States
Recruiting Study Coordinator
207-844-5628
Mercy Hospital Saint Louis - David C. Pratt Cancer Center ( Site 0095)
Saint Louis, Missouri 63141
United States
Recruiting Study Coordinator
314-251-7061
Comprehensive Cancer Centers of Nevada ( Site 0005)
Las Vegas, Nevada 89169
United States
Recruiting Study Coordinator
702-952-3400
Thomas Jefferson University Hospital ( Site 0051)
Philadelphia, Pennsylvania 19107
United States
Recruiting Study Coordinator
215-955-9548
Virginia Cancer Institute ( Site 0099)
Richmond, Virginia 23230
United States
Recruiting Study Coordinator
804-287-3000
Cancer Care Northwest ( Site 0009)
Spokane, Washington 99218
United States
Recruiting Study Coordinator
509-228-1680
Centro de Investigaciones Clinicas - Clinica Viedma ( Site 0585)
Viedma, Rio Negro R8500ACE
Argentina
Recruiting Study Coordinator
+5492920601693
Instituto de Investigaciones Metabolicas ( Site 0589)
Buenos Aires, C1012AAR
Argentina
Recruiting Study Coordinator
+5491157654803
CEMAIC ( Site 0581)
Cordoba, X5008HHW
Argentina
Recruiting Study Coordinator
+5493516212584
Macquarie University ( Site 0151)
North Ryde, New South Wales 2109
Australia
Recruiting Study Coordinator
+61298459553
Juravinski Cancer Centre ( Site 0101)
Hamilton, Ontario L8V 5C2
Canada
Recruiting Study Coordinator
9053879495
Lakeridge Health ( Site 0103)
Oshawa, Ontario L1G 2B9
Canada
Recruiting Study Coordinator
9055768711
Sunnybrook Research Institute ( Site 0106)
Toronto, Ontario M4N 3M5
Canada
Recruiting Study Coordinator
41648050005739
CIUSSS de l Estrie Centre Hospitalier Universitaire de Sherbrooke ( Site 0102)
Sherbrooke, Quebec J1H 5N4
Canada
Recruiting Study Coordinator
819346111012811
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 0104)
Quebec, G1R 2J6
Canada
Recruiting Study Coordinator
418525444420414
Rigshospitalet ( Site 0680)
Copenhagen, 2100
Denmark
Recruiting Study Coordinator
+4535453545
Herlev Hospital ( Site 0681)
Herlev, 2730
Denmark
Recruiting Study Coordinator
+4538682200
Odense Universitetshospital ( Site 0682)
Odense, 5000
Denmark
Recruiting Study Coordinator
+4530343148
Centre Hospitalier de la Cote Basque ( Site 0239)
Bayonne, 64109
France
Recruiting Study Coordinator
+33559443535
CHU de Bordeaux- Hopital Saint Andre ( Site 0235)
Bordeaux, 33075
France
Recruiting Study Coordinator
+33556795808
CHD Vendee ( Site 0251)
La Roche sur Yon, 85925
France
Recruiting Study Coordinator
+33251446141
Hopital de la Timone ( Site 0246)
Marseille, 13005
France
Recruiting Study Coordinator
+33491385708
Centre de Cancerologie du Grand Montpellier ( Site 0249)
Montpellier, 34070
France
Recruiting Study Coordinator
+33467926155
Centre D Oncologie de Gentilly ( Site 0240)
Nancy, 54100
France
Recruiting Study Coordinator
+33383935005
Institut Curie ( Site 0237)
Paris, 75005
France
Recruiting Study Coordinator
+33144324675
CHU Poitiers ( Site 0253)
Poitiers, 86021
France
Recruiting Study Coordinator
+33549441496
CHIC Quimper ( Site 0245)
Quimper, 29107
France
Recruiting Study Coordinator
+33251446161
Centre Rene Gauducheau ICO ( Site 0250)
Saint Herblain, 44805
France
Recruiting Study Coordinator
+33240679976
Hopital Civil-CHU de Strasbourg ( Site 0232)
Strasbourg, 67091
France
Recruiting Study Coordinator
+33388116768
Institut Gustave Roussy ( Site 0243)
Villejuif, 94805
France
Recruiting Study Coordinator
+33142115216
Universitaetsmedizin Goettingen ( Site 0281)
Gottingen, 37075
Germany
Recruiting Study Coordinator
+4955139175669
Universitaetsklinikum Hamburg-Eppendorf ( Site 0282)
Hamburg, 20246
Germany
Recruiting Study Coordinator
+4940741058774
Klinikum der Eberhard-Karls-Universitaet Tuebingen ( Site 0271)
Tuebingen, 72076
Germany
Recruiting Study Coordinator
+4970712987235
Orszagos Onkologiai Intezet ( Site 0503)
Budapest, 1122
Hungary
Recruiting Study Coordinator
+3612248600
Somogy Megyei Kaposi Mor Oktato Korhaz ( Site 0504)
Kaposvar, 7400
Hungary
Recruiting Study Coordinator
+36304805269
Bacs-Kiskun Megyei Korhaz ( Site 0510)
Kecskemet, 6000
Hungary
Recruiting Study Coordinator
+36304913443
Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz ( Site 0506)
Miskolc, 3526
Hungary
Recruiting Study Coordinator
+36302780644
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet ( Site 0507)
Szolnok, 5000
Hungary
Recruiting Study Coordinator
+36209323256
Rambam Medical Center ( Site 0552)
Haifa, 3109601
Israel
Recruiting Study Coordinator
+97247776750
Shaare Zedek Medical Center ( Site 0559)
Jerusalem, 9103102
Israel
Recruiting Study Coordinator
+97226555727
Hadassah Ein Kerem Medical Center ( Site 0558)
Jerusalem, 9112001
Israel
Recruiting Study Coordinator
+972505172315
Meir Medical Center ( Site 0554)
Kfar Saba, 4428164
Israel
Recruiting Study Coordinator
+97297471606
Rabin Medical Center ( Site 0553)
Petach-Tikwa, 4941492
Israel
Recruiting Study Coordinator
+97239378074
Sheba Medical Center ( Site 0551)
Ramat Gan, 5265601
Israel
Recruiting Study Coordinator
+97235302191
Assaf Harofeh Medical Center ( Site 0556)
Zerifin, 7030001
Israel
Recruiting Study Coordinator
+97289779715
Centro di Riferimento Oncologico CRO ( Site 0304)
Aviano, PN 33081
Italy
Recruiting Study Coordinator
+390434659048
Istituto Tumori Giovanni Paolo II ( Site 0306)
Bari, 70124
Italy
Recruiting Study Coordinator
+390805555420
Policlinico S. Orsola - Malpighi (Bologna) ( Site 0302)
Bologna, 40138
Italy
Recruiting Study Coordinator
+390512142204
Azienda Ospedaliera per l Emergenza Cannizzaro ( Site 0305)
Catania, 95126
Italy
Recruiting Study Coordinator
+390957262082
ASST Grande Ospedale Metropolitano Niguarda ( Site 0307)
Milano, 20162
Italy
Recruiting Study Coordinator
+390264442291
Azienda Ospedaliera Santa Maria ( Site 0303)
Terni, 05100
Italy
Recruiting Study Coordinator
+390744205410
Hirosaki University Hospital ( Site 0123)
Hirosaki, Aomori 036-8563
Japan
Recruiting Study Coordinator
+81172335111
National Cancer Center Hospital East ( Site 0128)
Kashiwa, Chiba 277-8577
Japan
Recruiting Study Coordinator
+81471331111
Ehime University Hospital ( Site 0137)
Toon, Ehime 791-0295
Japan
Recruiting Study Coordinator
+81899645111
Sapporo Medical University Hospital ( Site 0122)
Sapporo, Hokkaido 060-8543
Japan
Recruiting Study Coordinator
+81116112111
University of Tsukuba Hospital ( Site 0126)
Tsukuba, Ibaraki 305-8576
Japan
Recruiting Study Coordinator
+81298533900
Kitasato University Hospital ( Site 0129)
Sagamihara, Kanagawa 252-0375
Japan
Recruiting Study Coordinator
+81427788111
Nara Medical University Hospital ( Site 0133)
Kashihara, Nara 634-8522
Japan
Recruiting Study Coordinator
+81744223051
Saitama Medical University International Medical Center ( Site 0125)
Hidaka, Saitama 350-1298
Japan
Recruiting Study Coordinator
+81429844111
Yamaguchi University Hospital ( Site 0135)
Ube, Yamaguchi 755-8505
Japan
Recruiting Study Coordinator
+81836222111
Akita University Hospital ( Site 0124)
Akita, 010-8543
Japan
Recruiting Study Coordinator
+81188341111
Chiba Cancer Center ( Site 0127)
Chiba, 260-8717
Japan
Recruiting Study Coordinator
+81432645431
Nagasaki University Hospital ( Site 0136)
Nagasaki, 852-8501
Japan
Recruiting Study Coordinator
+81958197200
Osaka City University Hospital ( Site 0132)
Osaka, 545-8586
Japan
Recruiting Study Coordinator
+81666452121
Tokushima University Hospital ( Site 0134)
Tokushima, 770-8503
Japan
Recruiting Study Coordinator
+81886313111
Medical Hospital, Tokyo Medical And Dental University ( Site 0130)
Tokyo, 113-8519
Japan
Recruiting Study Coordinator
+81338136111
Chungnam National University Hospital ( Site 0195)
Daejeon, Chungnam 35015
Korea, Republic of
Recruiting Study Coordinator
+82613797623
National Cancer Center ( Site 0196)
Goyang-si, 10408
Korea, Republic of
Recruiting Study Coordinator
+82319201678
Chonnam National University Hwasun Hospital ( Site 0194)
Hwasun Gun, 58128
Korea, Republic of
Recruiting Study Coordinator
+82613797623
Korea University Anam Hospital ( Site 0197)
Seoul, 02841
Korea, Republic of
Recruiting Study Coordinator
+82613797623
Seoul National University Hospital ( Site 0191)
Seoul, 03080
Korea, Republic of
Recruiting Study Coordinator
+82220722216
Severance Hospital ( Site 0192)
Seoul, 03722
Korea, Republic of
Recruiting Study Coordinator
+82222288137
Veterans Health Service Medical Center ( Site 0198)
Seoul, 05368
Korea, Republic of
Recruiting Study Coordinator
+82222251669
Samsung Medical Center ( Site 0193)
Seoul, 06351
Korea, Republic of
Recruiting Study Coordinator
+82234101767
Amphia Ziekenhuis Breda ( Site 0331)
Breda, 4819 EV
Netherlands
Recruiting Study Coordinator
+31765951130
Haga Ziekenhuis ( Site 0333)
Den Haag, 2545 AA
Netherlands
Recruiting Study Coordinator
+31702102605
Maastricht Universitair Medisch Centrum - MUMC ( Site 0334)
Maastricht, 6229 HX
Netherlands
Recruiting Study Coordinator
+31433876543
Erasmus MC ( Site 0332)
Rotterdam, 3015 GD
Netherlands
Recruiting Study Coordinator
+31107041505
Szpital Miejski im. Jana Pawła II w Bielsku-Białej ( Site 0542)
Bielsko-Biala, 43-300
Poland
Recruiting Study Coordinator
+48603075937
Europejskie Centrum Zdrowia Otwock ( Site 0532)
Otwock, 05-400
Poland
Recruiting Study Coordinator
+48601200599
Urologica Praktyka Lekarska Adam Marcheluk ( Site 0543)
Siedlce, 08-110
Poland
Recruiting Study Coordinator
+48504283093
Szpital Wojewodzki ( Site 1062)
Tarnow, 33-100
Poland
Recruiting Study Coordinator
+48602280826
Magodent Szpital Elblaska ( Site 0541)
Warszawa, 01-748
Poland
Recruiting Study Coordinator
+48691666578
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego ( Site 0535)
Wroclaw, 50-556
Poland
Recruiting Study Coordinator
+48601772623
Russian Scientific Center of Roentgenoradiology ( Site 0424)
Moscow, 117997
Russian Federation
Recruiting Study Coordinator
+79166590224
Central Clinical Hospital with Polyclinic ( Site 0415)
Moscow, 121359
Russian Federation
Recruiting Study Coordinator
+74955300891
Medical Rehabilitation Center ( Site 0411)
Moscow, 125367
Russian Federation
Recruiting Study Coordinator
+79264375889
Murmansk Regional Oncology Dispensary ( Site 0420)
Murmansk, 183057
Russian Federation
Recruiting Study Coordinator
+79217252994
Volga District Medical Center Federal Medical and Biological Agency ( Site 0413)
Nizhny Novgorod, 603074
Russian Federation
Recruiting Study Coordinator
+78314216977
Omsk Clinical Oncology Dispensary ( Site 0418)
Omsk, 644013
Russian Federation
Recruiting Study Coordinator
+73812601724
Clinical Hospital Saint Luka ( Site 0421)
Saint-Petersburg, 194044
Russian Federation
Recruiting Study Coordinator
+79217252994
Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 0414)
Yaroslavl, 150054
Russian Federation
Recruiting Study Coordinator
+79106654167
Institut Catala d Oncologia Hospital Germans Trias i Pujol ( Site 0351)
Badalona, Barcelona 08916
Spain
Recruiting Study Coordinator
+34934978925
Hospital Teresa Herrera - Chuac ( Site 0357)
A Coruna, 15006
Spain
Recruiting Study Coordinator
+34981178000EXT292072
Hospital Infanta Cristina ( Site 0355)
Badajoz, 06080
Spain
Recruiting Study Coordinator
+34924218100
Hospital General Universitari Vall d Hebron ( Site 0358)
Barcelona, 08035
Spain
Recruiting Study Coordinator
+34934894350
Hospital Universitario Gregorio Maranon ( Site 0352)
Madrid, 28007
Spain
Recruiting Study Coordinator
+34914269393
Hospital Universitario HM Sanchinarro ( Site 0356)
Madrid, 28050
Spain
Recruiting Study Coordinator
+34917567984
Xarxa Assistencial Universitaria Manresa ( Site 0354)
Manresa, 08243
Spain
Recruiting Study Coordinator
+34938742112EXT5512
Kaohsiung Chang Gung Memorial Hospital ( Site 0217)
Kaohsiung, 833
Taiwan
Recruiting Study Coordinator
+886773171233267
Kaohsiung Medical University Chung-Ho Memorial Hospital ( Site 0216)
Kaoshiung, 807
Taiwan
Recruiting Study Coordinator
+886931199148
China Medical University Hospital ( Site 0213)
Taichung, 40447
Taiwan
Recruiting Study Coordinator
+886422052121
Taichung Veterans General Hospital ( Site 0214)
Taichung, 407
Taiwan
Recruiting Study Coordinator
+886423741215
National Cheng Kung University Hospital ( Site 0215)
Tainan, 70403
Taiwan
Recruiting Study Coordinator
+88662353535
National Taiwan University Hospital ( Site 0211)
Taipei, 10048
Taiwan
Recruiting Study Coordinator
+88622312345665238
Taipei Veterans General Hospital ( Site 0212)
Taipei, 11217
Taiwan
Recruiting Study Coordinator
+886228757519#315
Cukurova Universitesi Tıp Fakultesi Balcalı Hastanesi ( Site 0457)
Adana, 01330
Turkey
Recruiting Study Coordinator
+905335165643
Ankara Sehir Hastanesi ( Site 0455)
Ankara, 06800
Turkey
Recruiting Study Coordinator
+905555306271
Antalya Memorial Hospital Department of Medical Oncology ( Site 0461)
Antalya, 07020
Turkey
Recruiting Study Coordinator
+905076397700
Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 0454)
Istanbul, 34098
Turkey
Recruiting Study Coordinator
+905324167355
Medeniyet Uni. Goztepe Egitim ve Arast. Hast. ( Site 0459)
Istanbul, 34722
Turkey
Recruiting Study Coordinator
+905063509061
Ege Universitesi Tulay Aktas Onkoloji Hastanesi ( Site 0462)
İzmir, 35100
Turkey
Recruiting Study Coordinator
+905332117153
Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 0456)
Konya, 42080
Turkey
Recruiting Study Coordinator
+905322679838
Sakarya Universitesi Tip Fakultesi Arastirma Hastanesi ( Site 0460)
Sakarya, 54290
Turkey
Recruiting Study Coordinator
+905323233799
Lister Hospital ( Site 0376)
Stevenage, Herts SG1 4AB
United Kingdom
Recruiting Study Coordinator
+441438284298
Kent and Canterbury Hospital ( Site 0390)
Canterbury, Kent CT1 3NG
United Kingdom
Recruiting Study Coordinator
+441227766877
Nottingham University Hospital NHS Trust ( Site 0383)
Nottingham, Nottinghamshire NG5 1PB
United Kingdom
Recruiting Study Coordinator
+441159691169
Saint Bartholomew s Hospital - London ( Site 0386)
London, EC1A 7BE
United Kingdom
Recruiting Study Coordinator
+442078828505
University College London Hospital NHS Foundation Trust ( Site 0380)
London, NW1 2PG
United Kingdom
Recruiting Study Coordinator
+448451555000
Derriford Hospital ( Site 0388)
Plymouth, PL6 8DH
United Kingdom
Recruiting Study Coordinator
+441752430138
Royal Preston Hospital ( Site 0379)
Preston, PR2 9HT
United Kingdom
Recruiting Study Coordinator
+441772524656
Weston Park Hospital ( Site 0387)
Sheffield, S10 2SJ
United Kingdom
Recruiting Study Coordinator
+441142265072